1. Volume 15, Issue 1, Pages 94-105 (January 2012)
Reviewing the Cost-Effectiveness of Endocrine Early Breast Cancer Therapies: Influence of Differences in Modeling Methods on Outcomes 
Gerardus W.J. Frederix, MSc, Johan L. Severens, PhD, Anke M. Hövels, PhD, Jan A.M. Raaijmakers, PhD, Jan H.M. Schellens, MD, PhD 
Value in Health 
Volume 15, Issue 1, Pages (January 2012)
DOI: /j.jval
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Decision tree of included and excluded studies, with reasons for exclusions. CE, cost-effectiveness; CU, cost utility; NHSEED, National Health Service Economic Evaluation Database.
Value in Health  , DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Overview of time schedules and treatment duration of clinical trials applied in the pharmacoeconomic evaluation of endocrine therapies in early breast cancer (ATAC [32], Intergroup Exemestane Study [33], BIG 1-98 [34], and MA-17 [42].
Value in Health  , DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions